Creates 3rd largest global generics company with presence in 60+ markets$8.0+ billion anticipated pro forma combined 2012 revenueCombined management structured to immediately maximize combination value
PARSIPPANY, N.J. – October 31, 2012 – Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it has completed the acquisition of the Actavis Group for EUR4.25 billion. The combination creates the world’s third largest generic pharmaceutical company, with anticipated pro forma combined 2012 revenues in excess of $8 billion.
Medical Material Database Company Launches in India; Carna Medical Database to Establish a Medical...
New product lines strengthen Bayer’s animal health business in the U.S.
Leverkusen, January 4, 2013 – Bayer HealthCare announced today that it has received the necessary regulatory approval from the Federal Trade Commission to complete the acquisition of the U.S.-based animal health business of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA). As announced in September 2012, Bayer will pay up to 145 million USD which includes an upfront payment of 60 million USD plus a total of 85 million USD in milestone payments, which are linked to the successful and timely achievement of manufacturing and sales targets. The transaction includes a manufacturing site in St. Joseph, Missouri and around 300 employees.